Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

Fig. 2

SIRPα-αCD123 fusion antibodies preferentially bind to MOLM-13 cells in the presence of RBCs. A Binding of SIRPα-αCD123 fusion antibodies to MOLM-13 cells assessed by flow cytometry-based MFI ratio. The dotted line indicates an MFI ratio of 1.5 as the cut-off for positivity. Shown are the mean values from n = 2–3 independent experiments ± SEM. B Percentage of 100 nM antibodies targeting MOLM-13 cells or RBCs measured by flow cytometry at a 20-fold excess of RBCs. C MFI ratios of antibody binding to MOLM-13 cells in the presence of a 20-fold excess of RBCs. D MFI ratios of antibody binding to RBCs in the presence of MOLM-13 cells. The results of independent experiments with 4 different RBC donors represented as the mean ± SEM are shown. E Percentage of 100 nM antibodies targeting MOLM-13 cells or PBMCs measured by flow cytometry at a fivefold excess of PBMCs. Shown are mean values from n = 6 donors ± SEM. F Binding of SIRPα-αCD123 fusion antibodies to PBMCs assessed by flow cytometry-based MFI ratio. Shown are mean values from n = 5 donors ± SEM. G Binding of SIRPα-αCD123 fusion antibodies to platelets assessed by flow cytometry-based MFI ratio. Mean values from n = 4 donors ± SEM are shown. H Platelet aggregation induced by 100 nM antibody over time. Mean values from n = 4 donors ± SEM are shown. F and H p values are the same for both SIRPα-αCD123 fusion antibodies. Statistical differences were determined by one-way ANOVA using Holm–Sidak's post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page